Abstract

To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 35.7% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.

COVID-19 pandemic is a global health risk, but our understanding on the induced durable immunity remains scarce. Here the authors assess antibody responses in 869 convalescent COVID-19 patients to find that specific antibody titers reduce with time, and the RBD-IgG positive rate exceed 70% at 12 month post diagnosis, with male and older patients showing stronger responses.

Details

Title
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
Author
Li Cesheng 1 ; Ding, Yu 2 ; Wu, Xiao 1 ; Liang, Hong 2 ; Zhou, Zhijun 1 ; Xie, Yong 3 ; Li Taojing 4   VIAFID ORCID Logo  ; Wu Junzheng 5   VIAFID ORCID Logo  ; Lu Fengping 1 ; Lu, Feng 1 ; Mao, Min 1 ; Lin Lianzhen 1 ; Guo Huanhuan 1 ; Yue Shenglan 1 ; Wang, Feifei 1 ; Peng, Yan 1 ; Hu, Yong 1 ; Wang, Zejun 6 ; Yu, Jianhong 7 ; Zhang, Yong 8 ; Lu, Jia 6 ; Haoran, Ning 7 ; Yang, Huichuan 9 ; Fu Daoxing 8 ; He Yanlin 10 ; Zhou Dongbo 8 ; Du, Tao 8 ; Duan Kai 6 ; Dong Demei 8 ; Deng Kun 7 ; Zou Xia 7 ; Zhang, Ya 7 ; Zhou, Rong 8 ; Gao, Yang 8 ; Zhang, Xinxin 11 ; Yang, Xiaoming 12   VIAFID ORCID Logo 

 Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China 
 Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu, China; Beijing Tiantan Biological Products Co., Ltd, Beijing, China 
 Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China; Beijing Tiantan Biological Products Co., Ltd, Beijing, China 
 Beijing Tiantan Biological Products Co., Ltd, Beijing, China 
 Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu, China 
 Wuhan Institute of Biological Products Co. Ltd, Wuhan, China (GRID:grid.433798.2) (ISNI:0000 0004 0619 8601) 
 Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China (GRID:grid.433798.2) 
 Beijing Tiantan Biological Products Co., Ltd, Beijing, China (GRID:grid.433798.2) 
 China National Biotec Group Company Limited, Beijing, China (GRID:grid.433798.2) 
10  Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China (GRID:grid.433798.2); Beijing Tiantan Biological Products Co., Ltd, Beijing, China (GRID:grid.433798.2) 
11  Shanghai Jiao Tong University of Medicine, Research Laboratory of Clinical Virology, Ruijin Hospital and Ruijin Hospital North, National Research Center for Translational Medicine, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293) 
12  China National Biotec Group Company Limited, Beijing, China (GRID:grid.16821.3c) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2548894095
Copyright
© The Author(s) 2021. corrected publication 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.